Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Nutr.

Sec. Clinical Nutrition

Volume 12 - 2025 | doi: 10.3389/fnut.2025.1629154

Intermittent fasting in the treatment of type 2 diabetes

Provisionally accepted
Damian DyńkaDamian Dyńka1*Łukasz RodzeńŁukasz Rodzeń2Mateusz RodzeńMateusz Rodzeń2Dorota ŁojkoDorota Łojko3Adam DeptułaAdam Deptuła4Żaneta GrzywaczŻaneta Grzywacz4Sebastian KraszewskiSebastian Kraszewski5Karolina BartońKarolina Bartoń6Peter MartinPeter Martin7Anna Małgorzata DeptułaAnna Małgorzata Deptuła4Ken BerryKen Berry8David John UnwinDavid John Unwin9
  • 1Institute of Health Sciences, Faculty of Medical and Health Sciences, University of Siedlce, Siedlce, Poland
  • 2Rodzen Brothers Foundation, Wieleń, Poland
  • 3Department of Psychiatry, Poznan University of Medical Science, Poznań, Poland
  • 4Faculty of Production Engineering and Logistics, Opole University of Technology, Opole, Poland
  • 5Department of Biomedical Engineering, Faculty of Fundamental Problems of Technology, Wroclaw University of Science and Technology, Wrocław, Poland
  • 6Karolina Bartoń Food Coach, Warsaw, Poland
  • 7Funmed Clinics, Gothenburg, Sweden
  • 8Independent Researcher, Holladay, United States
  • 9The Collaborative Health Community Foundation, Oxford, United Kingdom

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

The increasing prevalence of type 2 diabetes mellitus (T2DM) has inspired researchers to investigate therapies and tools supporting the treatment of this disease. One such tool is intermittent fasting (IF). Given the nature and mechanism of action of IF it would be logical for it to have a beneficial effect on T2DM patients. This paper analyses the role of IF in the treatment of type 2 diabetes, used alongside standard recommendations, based on the current literature available to the authors. The authors discuss the benefits of IF in T2DM treatment, such as improved glycaemic control, improved insulin sensitivity, facilitated adherence to recommendations, weight reduction and lower risk of complications. The paper covers the results of meta-analyses, systematic reviews and randomised controlled trials (RCTs) and shows how novel technologies can make intermittent fasting easier.

Keywords: Type 2 diabetes mellitus (T2DM), Intermittent fasting (IF), Insulin Resistance, Glucose, Insulin, Body Weight, Novel technologies, artificial intelligence

Received: 15 May 2025; Accepted: 25 Jul 2025.

Copyright: © 2025 Dyńka, Rodzeń, Rodzeń, Łojko, Deptuła, Grzywacz, Kraszewski, Bartoń, Martin, Deptuła, Berry and Unwin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Damian Dyńka, Institute of Health Sciences, Faculty of Medical and Health Sciences, University of Siedlce, Siedlce, Poland

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material